This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
B

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenance Therapy in MM Guided by Multimodal MRD Negativity"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Ben Derman
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Ben Derman
230 views
June 11, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

12:42
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Liso-Cel in R/R MCL With Prior BTKi Thera…

Feat. L. Gordon
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson
12:49
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options…

Feat. P. Johnson
View All

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
17:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …

Feat. A. Jakubowiak
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
19:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
28:20
Indy Hematology Review

Managing Newly Diagnosed MM in 2024

Feat. S. Usmani
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
05:35
Saurabh Chhabra

Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence

24:23
MyCancerHaven

Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?

Feat. R. Vij, S. Al Hadidi
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
13:15
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?…

Feat. O. Landgren
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
14:09
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…

Feat. H. Hashmi
06:19
Insights from 2023 ASH Annual Meeting

Dara-KRd in NDMM Without ASCT: Final Analysis of a Ph2 Trial

Feat. B. Derman
35:37
University of Colorado Division of Hematology

2024 Updates on Multiple Myeloma Treatment

Feat. D. Sherbenou
03:42
Moffitt Cancer Center

Multiple Myeloma: What You Need to Know About New FDA Approvals of C…

Feat. D. Hansen
26:46
Samer Al Hadidi

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

11:38
Heinz Ludwig

Maintenance Therapy in Myeloma: Which Agent and for How Long?